Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. healthy male subjects~Exclusion criteria:~1. any relevant deviation from healthy conditions

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- treatment A (Type: ACTIVE_COMPARATOR): 1 tablet afatinib single dose
- treatment B (Type: EXPERIMENTAL): 2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
- treatment C (Type: EXPERIMENTAL): 2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day

Based on this trial design, predict the completion outcome and termination type (if applicable).